IMPLEMENTATION LEVEL

National

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

all

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 01 Apr 2021 | Removal date: open ended

Import tariff

On 22 March 2021, the Executive Committee of the Brazilian Foreign Trade Chamber (Gecex) issued Resolution No. 175 eliminating the import tariffs on Risanquizumab, Ranibizumab, as well as Escherichia Coli bacterial lysate capsules. The affected products were classified under the tariff subheadings NCM 3002.15.90 and 3002.90.92.

According to the regulation, prior to this announcement, the affected goods enjoyed an import duty of 2% in the case of Risanquizumab and Ranibizumab, and of 4% in the case of Escherichia Coli bacterial lysate capsules.

Resolution No. 175 is to enter into force on 1 April 2021.

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

352 Pharmaceutical products
3002 Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micr
300210 Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes
300290 Other

Please report this page in case you detect an inaccuracy in its content.